000088572512/31Q3false202320232023202300008857252023-01-012023-09-300000885725us-gaap:CommonStockMember2023-01-012023-09-300000885725bsx:SeniorNotedue2027Member2023-01-012023-09-30iso4217:USDxbrli:shares00008857252023-10-31xbrli:shares00008857252023-07-012023-09-30iso4217:USD00008857252022-07-012022-09-3000008857252022-01-012022-09-3000008857252023-09-3000008857252022-12-310000885725us-gaap:PreferredStockMember2023-06-300000885725us-gaap:PreferredStockMember2022-06-300000885725us-gaap:PreferredStockMember2022-12-310000885725us-gaap:PreferredStockMember2021-12-310000885725us-gaap:PreferredStockMember2023-07-012023-09-300000885725us-gaap:PreferredStockMember2022-07-012022-09-300000885725us-gaap:PreferredStockMember2023-01-012023-09-300000885725us-gaap:PreferredStockMember2022-01-012022-09-300000885725us-gaap:PreferredStockMember2023-09-300000885725us-gaap:PreferredStockMember2022-09-3000008857252023-06-3000008857252022-06-3000008857252021-12-310000885725us-gaap:CommonStockMember2023-07-012023-09-300000885725us-gaap:CommonStockMember2022-07-012022-09-300000885725us-gaap:CommonStockMember2023-01-012023-09-300000885725us-gaap:CommonStockMember2022-01-012022-09-3000008857252022-09-300000885725us-gaap:CommonStockMember2023-06-300000885725us-gaap:CommonStockMember2022-06-300000885725us-gaap:CommonStockMember2022-12-310000885725us-gaap:CommonStockMember2021-12-310000885725us-gaap:CommonStockMember2023-09-300000885725us-gaap:CommonStockMember2022-09-300000885725us-gaap:TreasuryStockCommonMember2023-06-300000885725us-gaap:TreasuryStockCommonMember2022-06-300000885725us-gaap:TreasuryStockCommonMember2022-12-310000885725us-gaap:TreasuryStockCommonMember2021-12-310000885725us-gaap:TreasuryStockCommonMember2023-07-012023-09-300000885725us-gaap:TreasuryStockCommonMember2022-07-012022-09-300000885725us-gaap:TreasuryStockCommonMember2023-01-012023-09-300000885725us-gaap:TreasuryStockCommonMember2022-01-012022-09-300000885725us-gaap:TreasuryStockCommonMember2023-09-300000885725us-gaap:TreasuryStockCommonMember2022-09-300000885725us-gaap:AdditionalPaidInCapitalMember2023-06-300000885725us-gaap:AdditionalPaidInCapitalMember2022-06-300000885725us-gaap:AdditionalPaidInCapitalMember2022-12-310000885725us-gaap:AdditionalPaidInCapitalMember2021-12-310000885725us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000885725us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000885725us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300000885725us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300000885725us-gaap:AdditionalPaidInCapitalMember2023-09-300000885725us-gaap:AdditionalPaidInCapitalMember2022-09-300000885725us-gaap:RetainedEarningsMember2023-06-300000885725us-gaap:RetainedEarningsMember2022-06-300000885725us-gaap:RetainedEarningsMember2022-12-310000885725us-gaap:RetainedEarningsMember2021-12-310000885725us-gaap:RetainedEarningsMember2023-07-012023-09-300000885725us-gaap:RetainedEarningsMember2022-07-012022-09-300000885725us-gaap:RetainedEarningsMember2023-01-012023-09-300000885725us-gaap:RetainedEarningsMember2022-01-012022-09-300000885725us-gaap:RetainedEarningsMember2023-09-300000885725us-gaap:RetainedEarningsMember2022-09-300000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000885725us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000885725us-gaap:NoncontrollingInterestMember2023-06-300000885725us-gaap:NoncontrollingInterestMember2022-06-300000885725us-gaap:NoncontrollingInterestMember2022-12-310000885725us-gaap:NoncontrollingInterestMember2021-12-310000885725us-gaap:NoncontrollingInterestMember2023-07-012023-09-300000885725us-gaap:NoncontrollingInterestMember2022-07-012022-09-300000885725us-gaap:NoncontrollingInterestMember2023-01-012023-09-300000885725us-gaap:NoncontrollingInterestMember2022-01-012022-09-300000885725us-gaap:NoncontrollingInterestMember2023-09-300000885725us-gaap:NoncontrollingInterestMember2022-09-300000885725bsx:RelievantMedsystemsIncMember2023-09-19xbrli:pure0000885725bsx:RelievantMedsystemsIncMember2023-09-192023-09-190000885725bsx:ApolloMember2023-04-040000885725bsx:ApolloMember2023-04-042023-04-040000885725bsx:AcotecMember2023-02-200000885725bsx:AcotecMember2023-02-202023-02-20iso4217:HKD0000885725bsx:AcotecMember2023-01-012023-09-300000885725bsx:ApolloMember2023-01-012023-09-300000885725bsx:AcotecMember2023-09-300000885725bsx:ApolloMember2023-09-300000885725bsx:AcotecMember2023-02-200000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:AcotecMember2023-09-300000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:AcotecMember2023-01-012023-09-300000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:AcotecMembersrt:WeightedAverageMember2023-09-300000885725us-gaap:CustomerRelationshipsMemberbsx:AcotecMember2023-09-300000885725us-gaap:CustomerRelationshipsMemberbsx:AcotecMember2023-01-012023-09-300000885725us-gaap:CustomerRelationshipsMemberbsx:AcotecMembersrt:WeightedAverageMember2023-09-300000885725bsx:AcotecMemberus-gaap:OtherIntangibleAssetsMember2023-09-300000885725bsx:AcotecMemberus-gaap:OtherIntangibleAssetsMember2023-01-012023-09-300000885725bsx:AcotecMembersrt:WeightedAverageMemberus-gaap:OtherIntangibleAssetsMember2023-09-300000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:ApolloMember2023-09-300000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:ApolloMember2023-01-012023-09-300000885725us-gaap:TechnologyBasedIntangibleAssetsMembersrt:WeightedAverageMemberbsx:ApolloMember2023-09-300000885725us-gaap:CustomerRelationshipsMemberbsx:ApolloMember2023-09-300000885725us-gaap:CustomerRelationshipsMemberbsx:ApolloMember2023-01-012023-09-300000885725us-gaap:CustomerRelationshipsMembersrt:WeightedAverageMemberbsx:ApolloMember2023-09-300000885725bsx:BaylisMedicalMember2022-02-142022-02-140000885725bsx:BaylisMedicalMember2023-01-012023-09-300000885725bsx:BaylisMedicalMember2023-09-300000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:BaylisMedicalMember2023-09-300000885725us-gaap:TechnologyBasedIntangibleAssetsMemberbsx:BaylisMedicalMember2023-01-012023-09-300000885725us-gaap:TechnologyBasedIntangibleAssetsMembersrt:WeightedAverageMemberbsx:BaylisMedicalMember2023-09-300000885725us-gaap:OtherIntangibleAssetsMemberbsx:BaylisMedicalMember2023-09-300000885725us-gaap:OtherIntangibleAssetsMemberbsx:BaylisMedicalMember2023-01-012023-09-300000885725srt:WeightedAverageMemberus-gaap:OtherIntangibleAssetsMemberbsx:BaylisMedicalMember2023-09-300000885725bsx:AllBusinessAcquisitionsMember2023-09-300000885725bsx:RDRegulatoryandCommercializationbasedMilestoneMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-09-300000885725bsx:RDRegulatoryandCommercializationbasedMilestoneMembersrt:MinimumMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-09-300000885725bsx:RDRegulatoryandCommercializationbasedMilestoneMembersrt:MaximumMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-09-300000885725bsx:RDRegulatoryandCommercializationbasedMilestoneMembersrt:WeightedAverageMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-09-300000885725bsx:RevenueBasedPaymentsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-09-300000885725srt:MinimumMemberbsx:RevenueBasedPaymentsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-09-30utr:Rate0000885725srt:MaximumMemberbsx:RevenueBasedPaymentsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-09-300000885725srt:WeightedAverageMemberbsx:RevenueBasedPaymentsMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-09-300000885725us-gaap:TechnologyBasedIntangibleAssetsMember2023-09-300000885725us-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310000885725us-gaap:PatentsMember2023-09-300000885725us-gaap:PatentsMember2022-12-310000885725us-gaap:OtherIntangibleAssetsMember2023-09-300000885725us-gaap:OtherIntangibleAssetsMember2022-12-310000885725us-gaap:GoodwillMember2023-09-300000885725us-gaap:GoodwillMember2022-12-310000885725us-gaap:InProcessResearchAndDevelopmentMember2023-09-300000885725us-gaap:InProcessResearchAndDevelopmentMember2022-12-310000885725us-gaap:TechnologyBasedIntangibleAssetsMember2023-09-300000885725us-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310000885725bsx:MedsurgMember2022-12-310000885725bsx:CardiovascularMember2022-12-310000885725bsx:MedsurgMember2023-01-012023-09-300000885725bsx:CardiovascularMember2023-01-012023-09-300000885725bsx:MedsurgMember2023-09-300000885725bsx:CardiovascularMember2023-09-300000885725bsx:December2027NotesMember2023-09-30iso4217:EUR0000885725us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-09-300000885725us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-09-30bsx:derivative_instrument0000885725us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2023-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2023-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberbsx:ForeigncurrencydenominatedindebtMemberus-gaap:NetInvestmentHedgingMember2023-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberbsx:ForeigncurrencydenominatedindebtMemberus-gaap:NetInvestmentHedgingMember2022-12-310000885725us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2023-09-300000885725us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-09-30bsx:units0000885725us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2023-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2023-07-012023-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMemberus-gaap:NetInvestmentHedgingMember2023-07-012023-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberbsx:ForeigncurrencydenominatedindebtMemberus-gaap:InterestExpenseMemberus-gaap:NetInvestmentHedgingMember2023-07-012023-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateContractMemberus-gaap:InterestExpenseMember2023-07-012023-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2022-07-012022-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMemberus-gaap:NetInvestmentHedgingMember2022-07-012022-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberbsx:ForeigncurrencydenominatedindebtMemberus-gaap:InterestExpenseMemberus-gaap:NetInvestmentHedgingMember2022-07-012022-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateContractMemberus-gaap:InterestExpenseMember2022-07-012022-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2023-01-012023-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMemberus-gaap:NetInvestmentHedgingMember2023-01-012023-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberbsx:ForeigncurrencydenominatedindebtMemberus-gaap:InterestExpenseMemberus-gaap:NetInvestmentHedgingMember2023-01-012023-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateContractMemberus-gaap:InterestExpenseMember2023-01-012023-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2022-01-012022-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMemberus-gaap:NetInvestmentHedgingMember2022-01-012022-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberbsx:ForeigncurrencydenominatedindebtMemberus-gaap:InterestExpenseMemberus-gaap:NetInvestmentHedgingMember2022-01-012022-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestRateContractMemberus-gaap:InterestExpenseMember2022-01-012022-09-300000885725us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-09-300000885725us-gaap:AccumulatedTranslationAdjustmentMember2023-07-012023-09-300000885725us-gaap:AccumulatedTranslationAdjustmentMember2022-07-012022-09-300000885725us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-09-300000885725us-gaap:CashFlowHedgingMemberus-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2023-09-300000885725us-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMemberus-gaap:NetInvestmentHedgingMember2023-09-300000885725us-gaap:CashFlowHedgingMemberus-gaap:InterestRateContractMemberus-gaap:InterestExpenseMember2023-09-300000885725us-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMember2023-07-012023-09-300000885725us-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-07-012022-09-300000885725us-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMember2023-01-012023-09-300000885725us-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMember2023-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMember2023-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000885725us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-09-300000885725us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2022-12-310000885725us-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-09-300000885725us-gaap:OtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentLiabilitiesMember2022-12-310000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-09-300000885725us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2022-12-310000885725us-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2023-09-300000885725us-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2022-12-310000885725us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000885725us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-09-300000885725us-gaap:FairValueMeasurementsRecurringMember2023-09-300000885725us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000885725us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000885725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310000885725us-gaap:FairValueMeasurementsRecurringMember2022-12-310000885725us-gaap:FairValueInputsLevel3Member2023-09-300000885725bsx:LicensingarrangementassetsMember2023-09-300000885725bsx:LicensingarrangementassetsMembersrt:WeightedAverageMember2023-09-300000885725bsx:LicensingarrangementliabilitiesMembersrt:MinimumMember2023-09-300000885725srt:MaximumMemberbsx:LicensingarrangementliabilitiesMember2023-09-300000885725bsx:LicensingarrangementliabilitiesMembersrt:WeightedAverageMember2023-09-300000885725bsx:LicensingarrangementassetsMember2023-01-012023-09-300000885725bsx:LicensingarrangementliabilitiesMember2023-01-012023-09-300000885725bsx:March2024NotesMember2023-09-300000885725bsx:March2024NotesMember2022-12-310000885725bsx:March2025NotesMember2023-09-300000885725bsx:March2025NotesMember2022-12-310000885725bsx:June2025NotesMember2023-09-300000885725bsx:June2025NotesMember2022-12-310000885725bsx:March2026NotesMember2023-09-300000885725bsx:March2026NotesMember2022-12-310000885725bsx:December2027NotesMember2022-12-310000885725bsx:March2028SeniorNotesMember2023-09-300000885725bsx:March2028SeniorNotesMember2022-12-310000885725bsx:March2028NotesMember2023-09-300000885725bsx:March2028NotesMember2022-12-310000885725bsx:March2029NotesMember2023-09-300000885725bsx:March2029NotesMember2022-12-310000885725bsx:June2030NotesMember2023-09-300000885725bsx:June2030NotesMember2022-12-310000885725bsx:March2031NotesMember2023-09-300000885725bsx:March2031NotesMember2022-12-310000885725bsx:March2034NotesMember2023-09-300000885725bsx:March2034NotesMember2022-12-310000885725bsx:November2035NotesMember2023-09-300000885725bsx:November2035NotesMember2022-12-310000885725bsx:March2039NotesMember2023-09-300000885725bsx:March2039NotesMember2022-12-310000885725bsx:January2040NotesMember2023-09-300000885725bsx:January2040NotesMember2022-12-310000885725bsx:March2049NotesMember2023-09-300000885725bsx:March2049NotesMember2022-12-310000885725us-gaap:SeniorNotesMember2023-09-300000885725us-gaap:SeniorNotesMember2022-12-310000885725us-gaap:CapitalLeaseObligationsMember2023-09-300000885725us-gaap:CapitalLeaseObligationsMember2022-12-310000885725us-gaap:RevolvingCreditFacilityMember2021-05-100000885725us-gaap:RevolvingCreditFacilityMember2021-05-102021-05-100000885725us-gaap:RevolvingCreditFacilityMember2022-12-310000885725us-gaap:RevolvingCreditFacilityMember2023-09-300000885725bsx:CurrentRequirementMember2023-09-300000885725bsx:ActualCovenantMember2023-09-300000885725bsx:RequirementAsOfDecember312021AndThroughRemainingTermOfFacilityMember2023-09-300000885725bsx:RequirementFourSucceedingQuartersFollowingQualifiedAcquisitionMember2023-09-300000885725bsx:RequirementfifthquarterfollowingqualifiedacquisitionMember2023-09-300000885725bsx:RequirementSixthQuarterFollowingQualifiedAcquisitionMember2023-09-300000885725bsx:RequirementSeventhQuarterFollowingQualifiedAcquisitionMember2023-09-300000885725bsx:RequirementEighthQuarterFollowingQualifiedAcquisitionAndThroughRemainingTermOfFacilityMember2023-09-300000885725us-gaap:CommercialPaperMember2023-01-012023-09-300000885725bsx:TheOfferingAggregatePrincipalAmountMember2023-09-300000885725bsx:TheOfferingEarlyRedemptionOfCombinedAggregatePrincipalSNMember2022-03-310000885725bsx:EuroDenominatedFactoringArrangementsMember2023-09-300000885725bsx:EuroDenominatedFactoringArrangementsMember2023-01-012023-09-300000885725bsx:EuroDenominatedFactoringArrangementsMember2022-12-310000885725bsx:EuroDenominatedFactoringArrangementsMember2022-01-012022-12-310000885725bsx:YenDenominatedFactoringArrangementsMember2023-09-300000885725bsx:YenDenominatedFactoringArrangementsMember2023-01-012023-09-300000885725bsx:YenDenominatedFactoringArrangementsMember2022-12-310000885725bsx:YenDenominatedFactoringArrangementsMember2022-01-012022-12-310000885725bsx:RenminbiDenominatedFactoringArrangementsMember2023-09-300000885725bsx:RenminbiDenominatedFactoringArrangementsMember2023-01-012023-09-300000885725bsx:RenminbiDenominatedFactoringArrangementsMember2022-12-310000885725bsx:RenminbiDenominatedFactoringArrangementsMember2022-01-012022-12-3100008857252023-01-312023-01-310000885725bsx:A550MCPSSeriesAMember2020-05-270000885725bsx:A550MCPSSeriesAMember2020-05-272020-05-270000885725bsx:A550MCPSSeriesAMember2023-09-300000885725us-gaap:EmployeeStockOptionMember2023-07-012023-09-300000885725us-gaap:EmployeeStockOptionMember2022-07-012022-09-300000885725us-gaap:EmployeeStockOptionMember2023-01-012023-09-300000885725us-gaap:EmployeeStockOptionMember2022-01-012022-09-300000885725bsx:A550MCPSSeriesAMember2023-07-012023-09-300000885725bsx:A550MCPSSeriesAMember2022-07-012022-09-300000885725bsx:A550MCPSSeriesAMember2023-01-012023-09-300000885725bsx:A550MCPSSeriesAMember2022-01-012022-09-3000008857252020-12-14bsx:reportablesegments0000885725bsx:MedsurgMember2023-07-012023-09-300000885725bsx:MedsurgMember2022-07-012022-09-300000885725bsx:MedsurgMember2022-01-012022-09-300000885725bsx:CardiovascularMember2023-07-012023-09-300000885725bsx:CardiovascularMember2022-07-012022-09-300000885725bsx:CardiovascularMember2022-01-012022-09-300000885725bsx:BSXReportableSegmentsMember2023-07-012023-09-300000885725bsx:BSXReportableSegmentsMember2022-07-012022-09-300000885725bsx:BSXReportableSegmentsMember2023-01-012023-09-300000885725bsx:BSXReportableSegmentsMember2022-01-012022-09-300000885725bsx:TotalAllocatedToReportableSegmentsMember2023-07-012023-09-300000885725bsx:TotalAllocatedToReportableSegmentsMember2022-07-012022-09-300000885725bsx:TotalAllocatedToReportableSegmentsMember2023-01-012023-09-300000885725bsx:TotalAllocatedToReportableSegmentsMember2022-01-012022-09-300000885725bsx:CorporateExpensesincludinghedgingactivitiesMember2023-07-012023-09-300000885725bsx:CorporateExpensesincludinghedgingactivitiesMember2022-07-012022-09-300000885725bsx:CorporateExpensesincludinghedgingactivitiesMember2023-01-012023-09-300000885725bsx:CorporateExpensesincludinghedgingactivitiesMember2022-01-012022-09-300000885725bsx:SpecialChargesMember2023-07-012023-09-300000885725bsx:SpecialChargesMember2022-07-012022-09-300000885725bsx:SpecialChargesMember2023-01-012023-09-300000885725bsx:SpecialChargesMember2022-01-012022-09-30bsx:business0000885725bsx:GlobalEndoscopyEndoReportingUnitMembercountry:US2023-07-012023-09-300000885725us-gaap:NonUsMemberbsx:GlobalEndoscopyEndoReportingUnitMember2023-07-012023-09-300000885725bsx:GlobalEndoscopyEndoReportingUnitMember2023-07-012023-09-300000885725bsx:GlobalEndoscopyEndoReportingUnitMembercountry:US2022-07-012022-09-300000885725us-gaap:NonUsMemberbsx:GlobalEndoscopyEndoReportingUnitMember2022-07-012022-09-300000885725bsx:GlobalEndoscopyEndoReportingUnitMember2022-07-012022-09-300000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMembercountry:US2023-07-012023-09-300000885725us-gaap:NonUsMemberbsx:GlobalUrologyandPelvicHealthReportingUnitMember2023-07-012023-09-300000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMember2023-07-012023-09-300000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMembercountry:US2022-07-012022-09-300000885725us-gaap:NonUsMemberbsx:GlobalUrologyandPelvicHealthReportingUnitMember2022-07-012022-09-300000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMember2022-07-012022-09-300000885725bsx:GlobalNeuromodulationNmReportingUnitMembercountry:US2023-07-012023-09-300000885725us-gaap:NonUsMemberbsx:GlobalNeuromodulationNmReportingUnitMember2023-07-012023-09-300000885725bsx:GlobalNeuromodulationNmReportingUnitMember2023-07-012023-09-300000885725bsx:GlobalNeuromodulationNmReportingUnitMembercountry:US2022-07-012022-09-300000885725us-gaap:NonUsMemberbsx:GlobalNeuromodulationNmReportingUnitMember2022-07-012022-09-300000885725bsx:GlobalNeuromodulationNmReportingUnitMember2022-07-012022-09-300000885725bsx:MedsurgMembercountry:US2023-07-012023-09-300000885725us-gaap:NonUsMemberbsx:MedsurgMember2023-07-012023-09-300000885725bsx:MedsurgMembercountry:US2022-07-012022-09-300000885725us-gaap:NonUsMemberbsx:MedsurgMember2022-07-012022-09-300000885725bsx:InterventionalCardiologyTherapiesMembercountry:US2023-07-012023-09-300000885725us-gaap:NonUsMemberbsx:InterventionalCardiologyTherapiesMember2023-07-012023-09-300000885725bsx:InterventionalCardiologyTherapiesMember2023-07-012023-09-300000885725bsx:InterventionalCardiologyTherapiesMembercountry:US2022-07-012022-09-300000885725us-gaap:NonUsMemberbsx:InterventionalCardiologyTherapiesMember2022-07-012022-09-300000885725bsx:InterventionalCardiologyTherapiesMember2022-07-012022-09-300000885725bsx:WatchmanMembercountry:US2023-07-012023-09-300000885725us-gaap:NonUsMemberbsx:WatchmanMember2023-07-012023-09-300000885725bsx:WatchmanMember2023-07-012023-09-300000885725bsx:WatchmanMembercountry:US2022-07-012022-09-300000885725us-gaap:NonUsMemberbsx:WatchmanMember2022-07-012022-09-300000885725bsx:WatchmanMember2022-07-012022-09-300000885725country:USbsx:CardiacRhythmManagementMember2023-07-012023-09-300000885725us-gaap:NonUsMemberbsx:CardiacRhythmManagementMember2023-07-012023-09-300000885725bsx:CardiacRhythmManagementMember2023-07-012023-09-300000885725country:USbsx:CardiacRhythmManagementMember2022-07-012022-09-300000885725us-gaap:NonUsMemberbsx:CardiacRhythmManagementMember2022-07-012022-09-300000885725bsx:CardiacRhythmManagementMember2022-07-012022-09-300000885725bsx:ElectrophysiologyEPMembercountry:US2023-07-012023-09-300000885725us-gaap:NonUsMemberbsx:ElectrophysiologyEPMember2023-07-012023-09-300000885725bsx:ElectrophysiologyEPMember2023-07-012023-09-300000885725bsx:ElectrophysiologyEPMembercountry:US2022-07-012022-09-300000885725us-gaap:NonUsMemberbsx:ElectrophysiologyEPMember2022-07-012022-09-300000885725bsx:ElectrophysiologyEPMember2022-07-012022-09-300000885725bsx:GlobalCardiologyReportingUnitMembercountry:US2023-07-012023-09-300000885725us-gaap:NonUsMemberbsx:GlobalCardiologyReportingUnitMember2023-07-012023-09-300000885725bsx:GlobalCardiologyReportingUnitMember2023-07-012023-09-300000885725bsx:GlobalCardiologyReportingUnitMembercountry:US2022-07-012022-09-300000885725us-gaap:NonUsMemberbsx:GlobalCardiologyReportingUnitMember2022-07-012022-09-300000885725bsx:GlobalCardiologyReportingUnitMember2022-07-012022-09-300000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMembercountry:US2023-07-012023-09-300000885725us-gaap:NonUsMemberbsx:GlobalPeripheralInterventionsPiReportingUnitMember2023-07-012023-09-300000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMember2023-07-012023-09-300000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMembercountry:US2022-07-012022-09-300000885725us-gaap:NonUsMemberbsx:GlobalPeripheralInterventionsPiReportingUnitMember2022-07-012022-09-300000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMember2022-07-012022-09-300000885725country:USbsx:CardiovascularMember2023-07-012023-09-300000885725us-gaap:NonUsMemberbsx:CardiovascularMember2023-07-012023-09-300000885725country:USbsx:CardiovascularMember2022-07-012022-09-300000885725us-gaap:NonUsMemberbsx:CardiovascularMember2022-07-012022-09-300000885725country:US2023-07-012023-09-300000885725us-gaap:NonUsMember2023-07-012023-09-300000885725country:US2022-07-012022-09-300000885725us-gaap:NonUsMember2022-07-012022-09-300000885725bsx:GlobalEndoscopyEndoReportingUnitMembercountry:US2023-01-012023-09-300000885725us-gaap:NonUsMemberbsx:GlobalEndoscopyEndoReportingUnitMember2023-01-012023-09-300000885725bsx:GlobalEndoscopyEndoReportingUnitMember2023-01-012023-09-300000885725bsx:GlobalEndoscopyEndoReportingUnitMembercountry:US2022-01-012022-09-300000885725us-gaap:NonUsMemberbsx:GlobalEndoscopyEndoReportingUnitMember2022-01-012022-09-300000885725bsx:GlobalEndoscopyEndoReportingUnitMember2022-01-012022-09-300000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMembercountry:US2023-01-012023-09-300000885725us-gaap:NonUsMemberbsx:GlobalUrologyandPelvicHealthReportingUnitMember2023-01-012023-09-300000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMember2023-01-012023-09-300000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMembercountry:US2022-01-012022-09-300000885725us-gaap:NonUsMemberbsx:GlobalUrologyandPelvicHealthReportingUnitMember2022-01-012022-09-300000885725bsx:GlobalUrologyandPelvicHealthReportingUnitMember2022-01-012022-09-300000885725bsx:GlobalNeuromodulationNmReportingUnitMembercountry:US2023-01-012023-09-300000885725us-gaap:NonUsMemberbsx:GlobalNeuromodulationNmReportingUnitMember2023-01-012023-09-300000885725bsx:GlobalNeuromodulationNmReportingUnitMember2023-01-012023-09-300000885725bsx:GlobalNeuromodulationNmReportingUnitMembercountry:US2022-01-012022-09-300000885725us-gaap:NonUsMemberbsx:GlobalNeuromodulationNmReportingUnitMember2022-01-012022-09-300000885725bsx:GlobalNeuromodulationNmReportingUnitMember2022-01-012022-09-300000885725bsx:MedsurgMembercountry:US2023-01-012023-09-300000885725us-gaap:NonUsMemberbsx:MedsurgMember2023-01-012023-09-300000885725bsx:MedsurgMembercountry:US2022-01-012022-09-300000885725us-gaap:NonUsMemberbsx:MedsurgMember2022-01-012022-09-300000885725bsx:InterventionalCardiologyTherapiesMembercountry:US2023-01-012023-09-300000885725us-gaap:NonUsMemberbsx:InterventionalCardiologyTherapiesMember2023-01-012023-09-300000885725bsx:InterventionalCardiologyTherapiesMember2023-01-012023-09-300000885725bsx:InterventionalCardiologyTherapiesMembercountry:US2022-01-012022-09-300000885725us-gaap:NonUsMemberbsx:InterventionalCardiologyTherapiesMember2022-01-012022-09-300000885725bsx:InterventionalCardiologyTherapiesMember2022-01-012022-09-300000885725bsx:WatchmanMembercountry:US2023-01-012023-09-300000885725us-gaap:NonUsMemberbsx:WatchmanMember2023-01-012023-09-300000885725bsx:WatchmanMember2023-01-012023-09-300000885725bsx:WatchmanMembercountry:US2022-01-012022-09-300000885725us-gaap:NonUsMemberbsx:WatchmanMember2022-01-012022-09-300000885725bsx:WatchmanMember2022-01-012022-09-300000885725country:USbsx:CardiacRhythmManagementMember2023-01-012023-09-300000885725us-gaap:NonUsMemberbsx:CardiacRhythmManagementMember2023-01-012023-09-300000885725bsx:CardiacRhythmManagementMember2023-01-012023-09-300000885725country:USbsx:CardiacRhythmManagementMember2022-01-012022-09-300000885725us-gaap:NonUsMemberbsx:CardiacRhythmManagementMember2022-01-012022-09-300000885725bsx:CardiacRhythmManagementMember2022-01-012022-09-300000885725bsx:ElectrophysiologyEPMembercountry:US2023-01-012023-09-300000885725us-gaap:NonUsMemberbsx:ElectrophysiologyEPMember2023-01-012023-09-300000885725bsx:ElectrophysiologyEPMember2023-01-012023-09-300000885725bsx:ElectrophysiologyEPMembercountry:US2022-01-012022-09-300000885725us-gaap:NonUsMemberbsx:ElectrophysiologyEPMember2022-01-012022-09-300000885725bsx:ElectrophysiologyEPMember2022-01-012022-09-300000885725bsx:GlobalCardiologyReportingUnitMembercountry:US2023-01-012023-09-300000885725us-gaap:NonUsMemberbsx:GlobalCardiologyReportingUnitMember2023-01-012023-09-300000885725bsx:GlobalCardiologyReportingUnitMember2023-01-012023-09-300000885725bsx:GlobalCardiologyReportingUnitMembercountry:US2022-01-012022-09-300000885725us-gaap:NonUsMemberbsx:GlobalCardiologyReportingUnitMember2022-01-012022-09-300000885725bsx:GlobalCardiologyReportingUnitMember2022-01-012022-09-300000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMembercountry:US2023-01-012023-09-300000885725us-gaap:NonUsMemberbsx:GlobalPeripheralInterventionsPiReportingUnitMember2023-01-012023-09-300000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMember2023-01-012023-09-300000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMembercountry:US2022-01-012022-09-300000885725us-gaap:NonUsMemberbsx:GlobalPeripheralInterventionsPiReportingUnitMember2022-01-012022-09-300000885725bsx:GlobalPeripheralInterventionsPiReportingUnitMember2022-01-012022-09-300000885725country:USbsx:CardiovascularMember2023-01-012023-09-300000885725us-gaap:NonUsMemberbsx:CardiovascularMember2023-01-012023-09-300000885725country:USbsx:CardiovascularMember2022-01-012022-09-300000885725us-gaap:NonUsMemberbsx:CardiovascularMember2022-01-012022-09-300000885725country:US2023-01-012023-09-300000885725us-gaap:NonUsMember2023-01-012023-09-300000885725country:US2022-01-012022-09-300000885725us-gaap:NonUsMember2022-01-012022-09-300000885725bsx:BSXReportableSegmentsMembercountry:US2023-07-012023-09-300000885725bsx:BSXReportableSegmentsMembercountry:US2022-07-012022-09-300000885725bsx:BSXReportableSegmentsMembercountry:US2023-01-012023-09-300000885725bsx:BSXReportableSegmentsMembercountry:US2022-01-012022-09-300000885725bsx:BSXReportableSegmentsMemberus-gaap:EMEAMember2023-07-012023-09-300000885725bsx:BSXReportableSegmentsMemberus-gaap:EMEAMember2022-07-012022-09-300000885725bsx:BSXReportableSegmentsMemberus-gaap:EMEAMember2023-01-012023-09-300000885725bsx:BSXReportableSegmentsMemberus-gaap:EMEAMember2022-01-012022-09-300000885725srt:AsiaPacificMemberbsx:BSXReportableSegmentsMember2023-07-012023-09-300000885725srt:AsiaPacificMemberbsx:BSXReportableSegmentsMember2022-07-012022-09-300000885725srt:AsiaPacificMemberbsx:BSXReportableSegmentsMember2023-01-012023-09-300000885725srt:AsiaPacificMemberbsx:BSXReportableSegmentsMember2022-01-012022-09-300000885725bsx:BSXReportableSegmentsMemberbsx:LatinAmericaandCanadaMember2023-07-012023-09-300000885725bsx:BSXReportableSegmentsMemberbsx:LatinAmericaandCanadaMember2022-07-012022-09-300000885725bsx:BSXReportableSegmentsMemberbsx:LatinAmericaandCanadaMember2023-01-012023-09-300000885725bsx:BSXReportableSegmentsMemberbsx:LatinAmericaandCanadaMember2022-01-012022-09-300000885725bsx:EmergingMarketsMember2023-07-012023-09-300000885725bsx:EmergingMarketsMember2022-07-012022-09-300000885725bsx:EmergingMarketsMember2023-01-012023-09-300000885725bsx:EmergingMarketsMember2022-01-012022-09-30
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File No. 1-11083
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
Delaware04-2695240
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
    300 Boston Scientific Way, Marlborough, Massachusetts                    01752-1234
        (Address of Principal Executive Offices)                         (Zip Code)
508 683-4000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareBSXNew York Stock Exchange
0.625% Senior Notes due 2027BSX27New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No
The number of shares outstanding of Common Stock, $0.01 par value per share, as of October 31, 2023 was 1,464,982,777.


Table of Contents

TABLE OF CONTENTS
  Page No.
 
   
   
 
   
 
   
 
   
 
   
   
   
   
   
   
 
2

Table of Contents

PART I
FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

Three Months Ended
September 30,
Nine Months Ended
September 30,
(in millions, except per share data)2023202220232022
Net sales$3,527 $3,170 $10,515 $9,440 
Cost of products sold1,101 979 3,198 2,945 
Gross profit2,426 2,191 7,317 6,495 
Operating expenses:
Selling, general and administrative expenses1,242 1,132 3,811 3,357 
Research and development expenses356 339 1,051 993 
Royalty expense11 11 35 34 
Amortization expense208 202 620 604 
Intangible asset impairment charges1 125 58 132 
Contingent consideration net expense (benefit)12 20 43 68 
Restructuring net charges (credits)15 4 51 18 
Litigation-related net charges (credits)(111) (111)42 
 1,733 1,833 5,558 5,248 
Operating income (loss)693 358 1,759 1,247 
Other income (expense):
Interest expense(66)(63)(200)(406)
Other, net(18)(51)(78)(96)
Income (loss) before income taxes610 245 1,480 745 
Income tax expense (benefit)105 57 392 188 
Net income (loss)504 188 1,088 558 
Preferred stock dividends (14)(23)(42)
Net income (loss) attributable to noncontrolling interests(0) (0) 
Net income (loss) attributable to Boston Scientific common stockholders$505 $174 $1,065 $516 
Net income (loss) per common share — basic$0.34 $0.12 $0.74 $0.36 
Net income (loss) per common share — diluted$0.34 $0.12 $0.73 $0.36 
Weighted-average shares outstanding
Basic1,464.5 1,431.6 1,448.8 1,429.7 
Diluted1,475.0 1,440.0 1,459.1 1,438.7 

Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
3

Table of Contents

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

Three Months Ended
September 30,
Nine Months Ended
September 30,
(in millions)2023202220232022
Net income (loss)$504 $188 $1,088 $558 
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment21 26 (7)39 
Net change in derivative financial instruments3 72 (25)229 
Net change in defined benefit pensions and other items(0)1 (5)1 
Other comprehensive income (loss)23 99 (37)269 
Comprehensive income (loss)$528 $287 $1,051 $827 
Comprehensive income attributable to noncontrolling interests(16) (16) 
Comprehensive income attributable to Boston Scientific common stockholders$511 $287 $1,035 $827 





































Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
4

Table of Contents

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS (UNAUDITED)
 As of
(in millions, except share and per share data)September 30, 2023December 31, 2022
ASSETS  
Current assets:  
Cash and cash equivalents$952 $928 
Trade accounts receivable, net2,101 1,970 
Inventories2,404 1,867 
Prepaid income taxes307 264 
Other current assets741 731 
Total current assets6,504 5,760 
Property, plant and equipment, net2,635 2,446 
Goodwill13,608 12,920 
Other intangible assets, net5,849 5,902 
Deferred tax assets3,840 3,942 
Other long-term assets1,605 1,500 
TOTAL ASSETS$34,043 $32,469 
LIABILITIES AND STOCKHOLDERS’ EQUITY  
Current liabilities:  
Current debt obligations$513 $20 
Accounts payable929 862 
Accrued expenses2,255 2,160 
Other current liabilities882 761 
Total current liabilities4,579 3,803 
Long-term debt8,386 8,915 
Deferred income taxes91 144 
Other long-term liabilities1,858 2,035 
Commitments and contingencies
Stockholders’ equity  
Preferred stock, $0.01 par value - authorized 50,000,000 shares - 0 shares issued as of September 30, 2023 and 10,062,500 shares as of December 31, 2022
  
Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,728,158,524 shares as of September 30, 2023 and 1,696,633,993 shares as of December 31, 2022
17 17 
Treasury stock, at cost - 263,289,848 shares as of September 30, 2023 and December 31, 2022
(2,251)(2,251)
Additional paid-in capital20,573 20,289 
Retained earnings/(Accumulated deficit)315 (750)
Accumulated other comprehensive income (loss), net of tax231 269 
Total stockholders’ equity18,886 17,573 
Noncontrolling interests243  
Total equity19,129 17,573 
TOTAL LIABILITIES AND EQUITY$34,043 $32,469 



Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
5

Table of Contents

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)
Three Months Ended
September 30,
Nine Months Ended
September 30,
(in millions, except share data)2023202220232022
Preferred stock shares issued
   Beginning 10,062,500 10,062,500 10,062,500 
Conversion of mandatory convertible preferred stock to common stock  (10,062,500) 
   Ending 10,062,500  10,062,500 
Common stock shares issued
   Beginning1,725,956,141 1,693,192,785 1,696,633,993 1,688,810,052 
Impact of stock-based compensation plans2,202,383 2,204,851 7,541,629 6,587,584 
Conversion of mandatory convertible preferred stock to common stock  23,982,902  
   Ending1,728,158,524 1,695,397,636 1,728,158,524 1,695,397,636 
Preferred stock
   Beginning$ $0 $0 $0 
Conversion of mandatory convertible preferred stock to common stock  (0) 
   Ending$ $0  $0 
Common stock
   Beginning$17 $17 $17 $17 
Impact of stock-based compensation plans0 0 0 0 
Conversion of mandatory convertible preferred stock to common stock  0  
   Ending$17 $17 $17 $17 
Treasury stock
Beginning$(2,251)$(2,251)$(2,251)$(2,251)
Repurchase of common stock    
Ending$(2,251)$(2,251)$(2,251)$(2,251)
Additional paid-in capital
Beginning$20,441 $20,103 $20,289 $19,986 
Impact of stock-based compensation plans132 116 285 233 
Ending$20,573 $20,219 $20,573 $20,219 
Retained earnings/(Accumulated deficit)
Beginning$(189)$(1,050)$(750)$(1,392)
Net income (loss)504 188 1,088 558 
Net income (loss) attributable to noncontrolling interests0  0  
Preferred stock dividends (14)(23)(42)
Ending$315 $(876)$315 $(876)
Accumulated other comprehensive income (loss), net of tax
Beginning$208 $433 $269 $263 
Changes in other comprehensive income (loss)23 99 (37)269 
Ending$231 $532 $231 $532 
Total stockholders' equity$18,886 $17,640 18,886 17,640 
Noncontrolling interests
Beginning$259 $   
Net income (loss) attributable to noncontrolling interests(0) (0) 
Changes in other comprehensive income (loss)(16) (16) 
Changes to noncontrolling ownership interest  259  
Ending$243 $ 243  
Total equity$19,129 $17,640 19,129 17,640 



Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
6

Table of Contents

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

Nine Months Ended September 30,
(in millions)20232022
Net income (loss)$1,088 $558 
Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities
Depreciation and amortization883 842 
Deferred and prepaid income taxes(74)(70)
Stock-based compensation expense174 165 
Goodwill and other intangible asset impairment charges58 132 
Net loss (gain) on investments and notes receivable48 46 
Contingent consideration net expense (benefit)43 68 
Inventory step-up amortization6 32 
Debt extinguishment costs 194 
Other, net33 92 
Increase (decrease) in operating assets and liabilities, excluding purchase accounting:
Trade accounts receivable(164)(176)
Inventories(601)(275)
Other assets(43)(298)
Accounts payable, accrued expenses and other liabilities95 (590)
Cash provided by (used for) operating activities1,546 719 
Investing activities:  
Purchases of property, plant and equipment and internal use software(444)(376)
Proceeds from sale of property, plant and equipment4 10 
Payments for acquisitions of businesses, net of cash acquired(1,018)(1,542)
Proceeds from (payments for) investments and acquisitions of certain technologies(89)(31)
Proceeds from royalty rights23 54 
Proceeds from (payments for) settlements of hedge contracts2 56 
Cash provided by (used for) investing activities(1,521)(1,828)
Financing activities:  
Payment of contingent consideration previously established in purchase accounting(39)(335)
Payments for royalty rights(50)(75)
Payments on short-term borrowings (250)
Net increase (decrease) in commercial paper(4)(1)
Payments on long-term borrowings and debt extinguishment costs (3,184)
Proceeds from long-term borrowings, net of debt issuance costs 3,270 
Cash dividends paid on preferred stock(28)(42)
Cash used to net share settle employee equity awards(54)(49)
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans165 117 
Cash provided by (used for) financing activities(10)(549)
Effect of foreign exchange rates on cash(8)(12)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents7 (1,671)
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period1,126 2,168 
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period$1,132 $497 





Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
7

Table of Contents

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(SUPPLEMENTAL INFORMATION)

Nine Months Ended September 30,
(in millions)20232022
Supplemental Information
Stock-based compensation expense$174 $165 
Non-cash impact of transferred royalty rights(23)(54)

As of September 30,
Reconciliation to amounts within the unaudited consolidated balance sheets:20232022
Cash and cash equivalents$952 $338 
Restricted cash and restricted cash equivalents included in Other current assets
123 112 
Restricted cash equivalents included in Other long-term assets
58 48 
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period$1,132 $497 
























Refer to notes to the unaudited consolidated financial statements. Amounts may not foot due to rounding.
8

Table of Contents

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE A – BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X, and they do not include all of the information and footnotes required by GAAP for complete financial statements. When used in this report, the terms, "we," "us," "our," and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. Accordingly, our unaudited consolidated financial statements and footnotes thereto should be read in conjunction with our audited consolidated financial statements and footnotes thereto included in Item 8 of our most recent Annual Report on Form 10-K.

The accompanying unaudited consolidated financial statements include the accounts of the Company's wholly owned- subsidiaries and entities for which the Company has a controlling financial interest. All intercompany balances and transactions have been eliminated in consolidation. In the first quarter of 2023, we acquired a majority stake investment in Acotec Scientific Holdings Limited (Acotec) and have elected to consolidate their financial statements on a one quarter lag.

Amounts reported in millions within this Quarterly Report on Form 10-Q are computed based on the amounts in thousands. As a result, the sum of the components may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.
Subsequent Events
We evaluate events occurring after the date of our accompanying unaudited consolidated balance sheet for potential recognition or disclosure in our financial statements. Those items requiring recognition in the financial statements have been recorded and disclosed accordingly.
Those items requiring disclosure (non-recognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note H – Commitments and Contingencies for further details.

NOTE B – ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS

Our accompanying unaudited consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. We have not presented supplemental pro forma financial information for completed acquisitions or divestitures given their results are not material to our accompanying unaudited consolidated financial statements. Further, transaction costs were immaterial to our accompanying unaudited consolidated financial statements and were expensed as incurred.

On September 19, 2023, we announced our entry into a definitive agreement to acquire 100 percent of Relievant Medsystems, Inc. (Relievant Medsystems), a privately held medical technology company that developed and commercialized the Intracept® Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain. The transaction price consists of an upfront cash payment of $850 million and additional contingent payments based on sales performance over the next three years. The transaction is expected to close in the first half of 2024, subject to customary closing conditions. Following the closing of the acquisition, we plan to integrate the Relievant Medsystems business into our Neuromodulation division.

2023 Acquisitions

On April 4, 2023, we completed our acquisition of 100 percent of the outstanding equity of Apollo Endosurgery, Inc. (Apollo), a public company which offers a portfolio of devices used during endoluminal procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity. The transaction consisted of an upfront cash payment of $636 million, net of cash acquired. The Apollo business is being integrated into our Endoscopy division.


9

Table of Contents

On February 20, 2023, we completed the acquisition of a majority stake investment in Acotec, a publicly traded Chinese manufacturer of drug-coated balloons used in the treatment of vascular and other diseases. We acquired approximately 65 percent of the outstanding shares of Acotec, for an upfront cash payment of HK$20.00 per share, or $519 million at foreign currency exchange rates at closing. The Acotec portfolio complements our existing Peripheral Interventions portfolio.

Purchase Price Allocation

We accounted for these transactions as business combinations in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, Business Combinations (FASB ASC Topic 805). The preliminary purchase prices were comprised of the amounts presented below:

(in millions)
Acotec(1)
Apollo
Payment for acquisition, net of cash acquired (2)
$381 $636 
$381 $636 
(1) Excludes approximately $140 million of cash on hand at the closing of the transaction
(2) Represents majority stake investment in Acotec

We recorded the assets acquired, liabilities assumed and specific to Acotec, the noncontrolling interest, at their respective fair values as of the closing of the transaction. The preliminary purchase price allocations were comprised of the following components and the final determination of the fair value of certain assets and liabilities will be completed within the measurement period in accordance with FASB ASC Topic 805:

(in millions)AcotecApollo
Goodwill$338 $379 
Amortizable intangible assets334 248 
Other assets acquired93 50 
Liabilities assumed(48)(33)
Net deferred tax liabilities(77)(7)
Fair value of noncontrolling interest(259) 
$381 $636 

The fair value of Acotec's noncontrolling interest was based on the publicly traded market value of the remaining 35 percent of the outstanding shares we did not acquire as of the transaction date and is presented within Stockholders' equity within our accompanying unaudited consolidated balance sheets. Goodwill was primarily established for Acotec due to opportunities for collaboration in research and development, manufacturing and commercial strategies and for Apollo due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies, none of which is deductible for tax purposes.

10

Table of Contents

We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Acotec:
Amortizable intangible assets:
Technology-related$308 1114%
Customer relationships15 1114%
Other intangible assets11 1314%
$334 
Apollo:
Amortizable intangible assets:
Technology-related$222 1112%
Customer relationships26 1112%
$248 

2022 Acquisition

On February 14, 2022, we completed our acquisition of Baylis Medical Company Inc. (Baylis Medical), a privately-held company which developed the radiofrequency (RF) NRG and VersaCrossTransseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access, which expanded our electrophysiology and structural heart product portfolios. The transaction consisted of an upfront cash payment of $1.463 billion, net of cash acquired, subject to closing adjustments. We are integrating the Baylis Medical business into our Cardiology division.

Purchase Price Allocation

We accounted for the acquisition of Baylis Medical as a business combination in accordance with FASB ASC Topic 805. The final purchase price was comprised of the amount presented below:

(in millions)
Payment for acquisition, net of cash acquired$1,463 
$1,463 

We recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The final purchase price allocation was comprised of the following components:

(in millions)
Goodwill$988 
Amortizable intangible assets657 
Other assets acquired112 
Liabilities assumed(287)
Net deferred tax liabilities(7)
$1,463 

Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies, and was deductible for tax purposes.

11

Table of Contents

We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
Technology-related$622 1111%
Other intangible assets36 1111%
$657 
Contingent Consideration
None of our acquisitions that closed during 2023 or 2022 contained contingent consideration arrangements. Changes in the fair value of our contingent consideration liability during the first nine months of 2023 associated with prior period acquisitions were as follows:

(in millions)
Balance as of December 31, 2022$149 
Contingent consideration net expense (benefit)43 
Contingent consideration payments(73)
Balance as of September 30, 2023$119 

The payments made during the first nine months of 2023 primarily related to our 2021 acquisition of Farapulse, Inc. As of September 30, 2023, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay associated with our completed acquisitions was approximately $380 million. Refer to Note B – Acquisitions and Strategic Investments to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for additional information.

The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:
Contingent Consideration LiabilityFair Value as of September 30, 2023Valuation TechniqueUnobservable InputRange
Weighted Average(1)
R&D, Regulatory and Commercialization-based Milestones$13 millionDiscounted Cash FlowDiscount Rate1%-2%1%
Probability of Payment10%-25%22%
Projected Year of Payment2023-20252024
Revenue-based Payments$106 millionDiscounted Cash FlowDiscount Rate6%-14%6%
Probability of Payment100%100%
Projected Year of Payment2023-20242023
(1)    Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Projected contingent payment amounts related to research and development (R&D), regulatory and commercialization-based milestones and revenue-based payments are discounted back to the current period, primarily using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of September 30, 2023.

12

Table of Contents

Strategic Investments

The aggregate carrying amount of our strategic investments was comprised of the following:

As of
(in millions)September 30, 2023December 31, 2022
Equity method investments$220 $188 
Measurement alternative investments(1, 2)
207 219 
$427 $407 
(1)    Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying unaudited consolidated statements of operations.
(2)    Includes publicly-held securities and convertible notes measured at fair value with changes in fair value recognized in Other, net within our accompanying unaudited consolidated statements of operations.

These investments are classified as Other long-term assets within our accompanying unaudited consolidated balance sheets, in accordance with GAAP and our accounting policies.

As of September 30, 2023, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $236 million, which represents amortizable intangible assets, in-process research and development (IPR&D), goodwill and deferred tax liabilities.

NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated goodwill impairment charges are as follows:
As of September 30, 2023As of December 31, 2022
(in millions)Gross Carrying AmountAccumulated Amortization/ Write-offsGross Carrying AmountAccumulated Amortization/ Write-offs
Technology-related$12,935 $(7,916)$12,397 $(7,378)
Patents477 (384)486 (394)
Other intangible assets2,036 (1,472)1,960 (1,400)
Amortizable intangible assets$15,447 $(9,772)$14,843 $(9,173)
    
Goodwill$23,508 $(9,900)$22,820 $(9,900)
IPR&D$54 $112 
Technology-related120 120 
Indefinite-lived intangible assets$174 $232 

The increase in our balance of goodwill and amortizable intangible assets is related primarily to our majority stake investment in Acotec completed in the first quarter of 2023 and our acquisition of Apollo completed in the second quarter of 2023.

The following represents a roll-forward of our goodwill balance by global reportable segment:
(in millions)MedSurgCardiovascularTotal
As of December 31, 2022$4,237 $8,684 $12,920 
Goodwill acquired379 338 717 
Impact of foreign currency fluctuations and purchase price adjustments(4)(25)(29)
As of September 30, 2023$4,611 $8,997 $13,608 

13

Table of Contents

Goodwill and Intangible Asset Impairments
We did not record any goodwill impairment charges in the first nine months of 2023 or 2022. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist.
We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. We identified the following reporting units for purposes of our annual goodwill impairment test: Interventional Cardiology, Rhythm Management, Peripheral Interventions, Endoscopy, Urology and Neuromodulation. Based on the criteria prescribed in FASB ASC Topic 350, we aggregated the Interventional Cardiology Therapies and Watchman components of our Cardiology operating segment into a single Interventional Cardiology reporting unit and aggregated the Cardiac Rhythm Management and Electrophysiology components of our Cardiology operating segment into a single Rhythm Management reporting unit.
In the second quarter of 2023, we performed our annual goodwill impairment test utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350, Intangibles - Goodwill and Other (FASB ASC Topic 350). The qualitative approach was used for testing reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units were tested using the quantitative approach. For the reporting units tested using the qualitative approach, after assessing the totality of events, it was determined that it was not more likely than not that the fair value of the reporting units was less than their carrying value, and it was not deemed necessary to proceed to the quantitative test. For the reporting unit tested using the quantitative approach, we determined that the fair value of the reporting unit exceeded the carrying value and concluded that goodwill was not impaired or at risk of impairment. There were no impairment indicators in the third quarter of 2023 that necessitated an interim impairment test.
In 2023, we recorded Intangible asset impairment charges of less than $1 million in the third quarter and recorded $58 million in the first nine months. In 2022, we recorded Intangible asset impairment charges of $125 million in the third quarter and $132 million in the first nine months. The impairment charges recorded in the first nine months of 2023 were primarily associated with the cancellation of an IPR&D program due to the incremental time and cost to complete the program and bring the technology to market. The impairment charges recorded in the third quarter and first nine months of 2022 were primarily associated with amortizable technology-related intangible assets that were initially established following our acquisition of Vertiflex, Inc., which was integrated into our Neuromodulation business, resulting from lower revenue projections due to reimbursement challenges.
We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. During the third quarter of 2023, we performed our annual IPR&D impairment test and evaluated our indefinite-lived core technology assets for impairment and concluded the assets were not impaired. We also verified that the classification of IPR&D projects and our indefinite-lived core technology assets recognized within our unaudited consolidated balance sheets continues to be appropriate.
Refer to Note A – Significant Accounting Policies to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for further discussion of our annual goodwill and intangible asset impairment testing.

14

Table of Contents

NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS

Derivative Instruments and Hedging Activities

We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and actively monitoring counterparty credit ratings. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.

Currency Hedging Instruments

Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities, forecasted intercompany and third-party transactions, and net investments in certain subsidiaries. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates.

The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in euro, British pound sterling, Swiss franc, Japanese yen, Chinese renminbi and Australian dollar. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecast. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.

Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, Derivatives and Hedging (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the Net change in derivative financial instruments component of Other comprehensive income (loss), net of tax (OCI) within our unaudited consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within Cost of products sold in our unaudited consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within Accumulated other comprehensive income (loss), net of tax (AOCI) to earnings at that time. The cash flows related to the derivative instruments designated as cash flow hedges are reported as operating activities in our consolidated statements of cash flows.

We designate certain euro-denominated debt as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the euro. As of September 30, 2023 and December 31, 2022, we designated as a net investment hedge our €900 million in aggregate principal amount of 0.625% euro-denominated senior notes issued in November 2019 and due in 2027 (2027 Notes). For these nonderivative instruments, we defer recognition of the foreign currency remeasurement gains and losses within the Foreign currency translation adjustment (CTA) component of Other comprehensive income (loss), net of tax. We reclassify these gains and losses to current period earnings within Other, net in our accompanying unaudited consolidated statements of operations only when the hedged item affects earnings, which would occur upon disposal or substantial liquidation of the underlying foreign subsidiary.

We also use forward currency contracts that are not part of designated hedging relationships as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within Other, net within our accompanying unaudited consolidated statements of operations.

15

Table of Contents

Interest Rate Hedging Instruments

Our interest rate risk relates primarily to U.S. dollar and euro-denominated borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements, we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.

We had no interest rate derivative instruments designated as cash flow hedges outstanding as of September 30, 2023 or December 31, 2022. In the event that we designate outstanding interest rate derivative instruments as cash flow hedges, we record the changes in the fair value of the derivatives within OCI until the underlying hedged transaction occurs.

The following table presents the contractual amounts of our hedging instruments outstanding:
(in millions)FASB ASC Topic 815 DesignationAs of
September 30, 2023December 31, 2022
Forward currency contractsCash flow hedge$2,343 $2,725 
Forward currency contractsNet investment hedge333 365 
Foreign currency-denominated debt(1)
Net investment hedge997 997 
Forward currency contractsNon-designated3,328 4,235 
Total Notional Outstanding$7,002 $8,321 
(1)    Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge.

As of September 30, 2023, the remaining time to maturity is within 36 months for all forward currency contracts designated as cash flow hedges and generally less than one year for all non-designated forward currency contracts. The forward currency contracts designated as net investment hedges generally mature between one and three years. The euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.

The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 in our accompanying unaudited consolidated statements of operations. Refer to Note M – Changes in Other Comprehensive Income for the total amounts relating to derivative and nonderivative instruments presented within our accompanying unaudited consolidated statements of comprehensive income (loss).

Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Three Months Ended September 30, 2023
Forward currency contracts
Cash flow hedges$54 $(12)$42 Cost of products sold$1,101 $(51)$11 $(39)
Net investment hedges(2)
12 (3)9 Interest expense66 (2)1 (2)
Foreign currency-denominated debt
Net investment hedges(3)
26 (6)20 Other, net18    
Interest rate derivative contracts
Cash flow hedges   Interest expense66 1 (0)1 

16

Table of Contents

Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Three Months Ended September 30, 2022
Forward currency contracts
Cash flow hedges$153 $(34)$119 Cost of products sold$979 $(61)$14 $(47)
Net investment hedges(2)
14 (16)(2)Interest expense63 (3)1 (2)
Foreign currency-denominated debt
Net investment hedges(3)
56 (13)43 Other, net51    
Interest rate derivative contracts
Cash flow hedges   Interest Expense63 1  1 


Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Nine Months Ended September 30, 2023
Forward currency contracts
Cash flow hedges$141 $(32)$109 Cost of products sold$3,198 $(176)$40 $(136)
Net investment hedges (2)
40 (9)31 Interest expense200 (7)2 (6)
Foreign currency-denominated debt
Net investment hedges (3)
8 (2)6 Other, net78    
Interest rate derivative contracts
Cash flow hedges Interest expense200 2 (0)2 

Effect of Hedging Relationships on Accumulated Other Comprehensive Income
Amount Recognized in OCI on Hedges
Unaudited Consolidated Statements of Operations(1)
Amount Reclassified from AOCI into Earnings
(in millions)Pre-Tax Gain (Loss)Tax Benefit (Expense)Gain (Loss) Net of TaxLocation of Amount Reclassified and Total Amount of Line ItemPre-Tax (Gain) LossTax (Benefit) Expense(Gain) Loss Net of Tax
Nine Months Ended September 30, 2022
Forward currency contracts
Cash flow hedges$412 $(93)$319 Cost of products sold$2,945 $(132)$30 $(102)
Net investment hedges (2)
63 (14)48 Interest expense406 (7)2 (6)
Foreign currency-denominated debt
Net investment hedges (3)
142 (32)110 Other, net96    
Interest rate derivative contracts
Cash flow hedges   Interest expense406 15 (3)12 
(1)    In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings.
(2)    For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current and prior period, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.
(3)    For our outstanding euro-denominated debt principal designated as a net investment hedge, the change in fair value attributable to changes in the spot rate is recorded in the CTA component of OCI. No amounts were reclassified from AOCI to current period earnings.
17

Table of Contents


As of September 30, 2023, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below:
(in millions)FASB ASC Topic 815 DesignationLocation on Unaudited Consolidated Statements of OperationsAmount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Designated Hedging Instrument
Forward currency contractsCash flow hedgeCost of products sold$221 
Forward currency contractsNet investment hedgeInterest expense9 
Interest rate derivative contractsCash flow hedgeInterest expense(2)

Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
Location on Unaudited Consolidated Statements of OperationsThree Months Ended September 30,Nine Months Ended September 30,
(in millions)2023202220232022
Net gain (loss) on currency hedge contractsOther, net$10 $(29)$13 $(93)
Net gain (loss) on currency transaction exposuresOther, net(16)(8)(42)48 
Net currency exchange gain (loss)$(6)$(38)$(30)$(45)

18

Table of Contents

Fair Value Measurements

FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures (FASB ASC Topic 820) and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:

 
Location on Unaudited Consolidated Balance Sheets(1)
As of
(in millions)September 30, 2023December 31, 2022
Derivative and Nonderivative Assets:   
Designated Hedging Instruments  
Forward currency contractsOther current assets$198 $196 
Forward currency contractsOther long-term assets155 149 
  353 345 
Non-Designated Hedging Instruments   
Forward currency contractsOther current assets43 36 
Total Derivative and Nonderivative Assets $396 $381 
Derivative and Nonderivative Liabilities:   
Designated Hedging Instruments  
Forward currency contractsOther current liabilities$1 $ 
Forward currency contractsOther long-term liabilities1 1 
Foreign currency-denominated debt(2)
Long-term debt946 952 
  947 953 
Non-Designated Hedging Instruments   
Forward currency contractsOther current liabilities30 52 
Total Derivative and Nonderivative Liabilities $977 $1,005 
(1)    We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.
(2)    Foreign currency-denominated debt is the €900 million debt principal associated with our 2027 Notes designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.

Recurring Fair Value Measurements
On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
19